EP1597400B8 - Methods of producing influenza vaccine compositions - Google Patents

Methods of producing influenza vaccine compositions Download PDF

Info

Publication number
EP1597400B8
EP1597400B8 EP04775805.7A EP04775805A EP1597400B8 EP 1597400 B8 EP1597400 B8 EP 1597400B8 EP 04775805 A EP04775805 A EP 04775805A EP 1597400 B8 EP1597400 B8 EP 1597400B8
Authority
EP
European Patent Office
Prior art keywords
methods
vaccine compositions
influenza vaccine
producing influenza
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04775805.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1597400A1 (en
EP1597400A4 (en
EP1597400B1 (en
Inventor
George Robert Trager
George Kemble
Richard M. Schwartz
Harshvardhan Mehta
Vu Truong-Le
Zhongying Chen
Alfred A. Pan
Eric Tsao
Chiaoyin Kathy Wang
Luisa Yee
Palani Balu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Priority to EP12155639A priority Critical patent/EP2481819A1/en
Publication of EP1597400A1 publication Critical patent/EP1597400A1/en
Publication of EP1597400A4 publication Critical patent/EP1597400A4/en
Application granted granted Critical
Publication of EP1597400B1 publication Critical patent/EP1597400B1/en
Publication of EP1597400B8 publication Critical patent/EP1597400B8/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/147—Microfiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Water Supply & Treatment (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
EP04775805.7A 2003-02-25 2004-02-25 Methods of producing influenza vaccine compositions Expired - Lifetime EP1597400B8 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12155639A EP2481819A1 (en) 2003-02-25 2004-02-25 Cross flow filtration in the production of stabilized influenza vaccine compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45018103P 2003-02-25 2003-02-25
US450181P 2003-02-25
PCT/US2004/005697 WO2005014862A1 (en) 2003-02-25 2004-02-25 Methods of producing inflenza vaccine compositions

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP12155639A Division-Into EP2481819A1 (en) 2003-02-25 2004-02-25 Cross flow filtration in the production of stabilized influenza vaccine compositions
EP12155639.3 Division-Into 2012-02-15

Publications (4)

Publication Number Publication Date
EP1597400A1 EP1597400A1 (en) 2005-11-23
EP1597400A4 EP1597400A4 (en) 2007-09-05
EP1597400B1 EP1597400B1 (en) 2012-08-22
EP1597400B8 true EP1597400B8 (en) 2013-10-09

Family

ID=34135009

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12155639A Ceased EP2481819A1 (en) 2003-02-25 2004-02-25 Cross flow filtration in the production of stabilized influenza vaccine compositions
EP04775805.7A Expired - Lifetime EP1597400B8 (en) 2003-02-25 2004-02-25 Methods of producing influenza vaccine compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12155639A Ceased EP2481819A1 (en) 2003-02-25 2004-02-25 Cross flow filtration in the production of stabilized influenza vaccine compositions

Country Status (9)

Country Link
US (5) US7262045B2 (ko)
EP (2) EP2481819A1 (ko)
JP (1) JP4617300B2 (ko)
KR (4) KR101190932B1 (ko)
CN (2) CN101804202B (ko)
AU (2) AU2004263813B8 (ko)
CA (2) CA2517181C (ko)
HK (1) HK1077085A1 (ko)
WO (1) WO2005014862A1 (ko)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
CN1788089A (zh) * 2002-07-03 2006-06-14 巴斯福股份公司 用于提高泛酸产量的微生物和方法
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
KR101190932B1 (ko) 2003-02-25 2012-10-16 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
WO2005018539A2 (en) * 2003-06-16 2005-03-03 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
WO2005077528A1 (en) * 2004-02-05 2005-08-25 Millipore Corporation Porous adsorptive or chromatographic media
ES2633471T3 (es) * 2004-10-06 2017-09-21 Medimmune, Llc Composiciones de vacuna contra la gripe estables a temperatura de refrigerador
AU2005314138B2 (en) 2004-12-08 2011-11-17 Medimmune, Llc Methods of producing influenza vaccine compositions
EP1831353B1 (en) 2004-12-23 2012-02-29 MedImmune, LLC Non-tumorigenic mdck cell line for propagating viruses
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
EP1869471B1 (en) * 2005-04-13 2016-06-08 Merial, Inc. Method for porcine circovirus production
AU2006252377A1 (en) * 2005-06-02 2006-12-07 Alza Corporation Method for terminal sterilization of transdermal delivery devices
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
KR20080025171A (ko) * 2005-06-21 2008-03-19 메드이뮨 백신즈 인코포레이티드 이종성 프로테아제를 발현시키기 위한 방법 및 조성물
AU2006278573A1 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US7534596B2 (en) * 2006-02-10 2009-05-19 Solohill Engineering, Inc. Method and device for producing vaccine
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008105931A2 (en) 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
WO2008076371A2 (en) * 2006-12-15 2008-06-26 Schering-Plough Ltd. Method for replicating influenza virus in culture
CN101631563B (zh) 2007-03-09 2013-07-24 大塚制药株式会社 含有流感疫苗的冻干制剂及其制备方法
JP5666905B2 (ja) * 2007-06-18 2015-02-12 メディミューン，エルエルシー ヘマグルチニンポリペプチド中に変化を有するインフルエンザｂウイルス
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
JP5705545B2 (ja) * 2007-11-12 2015-04-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア インフルエンザウイルスの複数のサブタイプに対する新規ワクチン
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
JP2011184299A (ja) * 2008-07-02 2011-09-22 Asahi Kasei Medical Co Ltd モノクローナル抗体を含む製剤の製造方法
CN102215865B (zh) 2008-09-24 2013-10-30 米迪缪尼有限公司 病毒纯化方法
CN102216450B (zh) 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
EA024262B1 (ru) * 2008-11-25 2016-09-30 Нанотерапьютикс Инк. СПОСОБ ПОЛУЧЕНИЯ ВЫСОКОИНФЕКЦИОННОГО ВИРУСА ГРИППА, СТАБИЛЬНОГО ПРИ НИЗКИХ pH
US9884105B2 (en) * 2008-12-16 2018-02-06 Ology Bioservices, Inc. Production of viral vaccine
CN101450209B (zh) * 2008-12-31 2012-01-25 中国人民解放军军事医学科学院微生物流行病研究所 透皮免疫流感多价疫苗的制备及其方法
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
WO2011005772A1 (en) 2009-07-06 2011-01-13 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
US20120077249A1 (en) * 2010-04-20 2012-03-29 Millipore Corporation Separation Of Virus And/Or Protein From Nucleic Acids By Primary Amines
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CN103282873B (zh) * 2010-11-12 2016-08-24 生命科技公司 用于实验室测定确认或验证的系统和方法
CN103501811B (zh) 2011-01-13 2016-03-30 变异生物技术公司 用于治疗病毒感染的组合物和方法
AU2012205315B2 (en) 2011-01-13 2017-05-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US20140024101A1 (en) 2011-04-08 2014-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for increasing the replication capacity of an influenza virus in cultured cells
US20140296106A1 (en) 2011-05-16 2014-10-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for screening substances capable of modulating the replication of an influenza virus
KR20140038530A (ko) * 2011-07-20 2014-03-28 애보트 바이올로지컬스 비.브이. 바이러스 항원 및 백신의 제조 방법
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
CN104023744A (zh) * 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
US9932620B2 (en) 2012-05-21 2018-04-03 Celsis Ltd. Methods, devices, and systems of detecting microorganisms
US20130309700A1 (en) * 2012-05-21 2013-11-21 Celsis International Limited Methods, devices, and systems of detecting microorganisms
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
EP2975119B1 (en) 2013-03-13 2020-03-11 ImmunoMax Co., Ltd. Cell strain having increased virus production ability and production method therefor
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
WO2015017673A1 (en) * 2013-08-01 2015-02-05 Medimmune, Llc Methods for producing influenza vaccine compositions
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
EP3125931A4 (en) * 2014-04-03 2017-09-20 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
JP6708636B2 (ja) 2014-06-18 2020-06-10 イミュノマックス カンパニー リミテッドＩｍｍｕｎｏｍａｘ Ｃｏ．， Ｌｔｄ． Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
CN107206063B (zh) 2014-12-01 2021-09-28 特兰斯吉恩股份有限公司 稳定的液体痘苗病毒制剂
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3381468A4 (en) * 2015-11-27 2019-06-05 Nitto Denko Corporation DRIED INFLUENZA VACCINE PREPARATION AND METHOD FOR PRODUCING A DRIED INFLUENZED VACCINE PREPARATION
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
MX2021007860A (es) 2018-12-28 2021-10-26 Transgene Poxvirux deficiente en m2.
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
KR20220153587A (ko) * 2020-03-12 2022-11-18 버베리안 노딕 에이/에스 폭스바이러스 안정성을 개선하는 조성물
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB660109A (en) * 1946-10-01 1951-10-31 American Cyanamid Co Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US3874999A (en) * 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
US4000257A (en) * 1975-12-22 1976-12-28 American Cyanamid Company Process for the purification of influenza virus vaccine
US4057626A (en) 1976-10-08 1977-11-08 Richardson-Merrell Inc. Process for detoxifying influenza B virus
US4338296A (en) * 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
JPS57114527A (en) * 1979-10-29 1982-07-16 Merck & Co Inc Vaccine stabilizer
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4512972A (en) * 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4512285A (en) * 1983-12-27 1985-04-23 Gof Manufacturing Company, Inc. Apparatus and method for egg turning during incubation
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
CA2065023A1 (en) * 1989-08-15 1991-02-16 Brent Dorval Stabilized vaccine compositions
AU2088992A (en) 1992-05-05 1993-11-11 Research Foundation For Microbial Diseases Of Osaka University, The Stabilized live vaccine
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
CA2235257A1 (en) 1995-10-20 1997-04-24 Yissum Research Development Company Of The Hebrew University Of Jerusale M Influenza vaccine
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6177082B1 (en) * 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
MXPA01006214A (es) 1998-12-17 2004-09-06 Aventis Pasteur Composicion inmunogenica multivalente que contiene una preparacion de virus de influenza y una composicion de subunidad del virus sincicial respiratorio.
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
JP4597454B2 (ja) * 1999-11-12 2010-12-15 ファイブローゲン、インコーポレーテッド 組換えゼラチン
CN1147316C (zh) * 2000-03-16 2004-04-28 辽宁天成生物制药研究所 流感病毒静水压技术灭活工艺制备疫苗的方法
BRPI0110607B8 (pt) 2000-04-28 2021-05-25 St Jude Childrens Res Hospital sistema baseado em plasmídeos, método para produzir um vírion de vírus com fita rna negativa, método para produzir um vírion orthomyxoviridae, método para produzir um vírion influenza, método para produzir um vírion influenzapatogênico, método para preparar uma vacina específica de vírus rna de fita negativa e método para gerar um vírus rna de fita negativa atenuado
BRPI0002694C1 (pt) 2000-06-19 2021-05-25 Fund Butantan processo de obtenção de vacina contra raiva em células vero, para uso humano
AU2002223560B2 (en) 2000-09-25 2006-06-29 Polymun Scientific Immunbiologische Forschung Gmbh Live influenza vaccine and method of manufacture
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
EP2545937A1 (en) * 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
WO2003087327A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
EP1572915A4 (en) * 2002-04-11 2011-01-05 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS BY SPRAY DRYING
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
KR101190932B1 (ko) 2003-02-25 2012-10-16 메디뮨 엘엘씨 인플루엔자 백신 조성물의 제조 방법
US20060110406A1 (en) * 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
ES2345492T3 (es) 2003-12-23 2010-09-24 Medimmune, Llc Sistema multiplasmido para la produccion del virus de la gripe.
EP2644696B1 (en) 2004-05-24 2015-07-15 MedImmune, LLC Method of increasing replication of a reassortant influenza virus in eggs.
ES2633471T3 (es) 2004-10-06 2017-09-21 Medimmune, Llc Composiciones de vacuna contra la gripe estables a temperatura de refrigerador

Also Published As

Publication number Publication date
US20040265987A1 (en) 2004-12-30
CN1777687A (zh) 2006-05-24
EP1597400A1 (en) 2005-11-23
EP2481819A1 (en) 2012-08-01
CA2517181A1 (en) 2005-02-17
KR101251902B1 (ko) 2013-04-08
JP2006519028A (ja) 2006-08-24
US20070161085A1 (en) 2007-07-12
US20160051660A1 (en) 2016-02-25
US7262045B2 (en) 2007-08-28
CA2517181C (en) 2013-07-16
US20130189305A1 (en) 2013-07-25
KR20130064826A (ko) 2013-06-18
WO2005014862B1 (en) 2005-06-16
CA2807534A1 (en) 2005-02-17
AU2004263813B2 (en) 2008-08-14
EP1597400A4 (en) 2007-09-05
AU2008230033A1 (en) 2008-11-13
AU2004263813A1 (en) 2005-02-17
WO2005014862A1 (en) 2005-02-17
KR101190932B1 (ko) 2012-10-16
CN101804202A (zh) 2010-08-18
KR20120103737A (ko) 2012-09-19
KR20120087892A (ko) 2012-08-07
HK1077085A1 (en) 2006-02-03
AU2004263813B8 (en) 2008-09-11
KR101357443B1 (ko) 2014-02-06
KR101360300B1 (ko) 2014-02-13
JP4617300B2 (ja) 2011-01-19
AU2008230033B2 (en) 2012-01-12
EP1597400B1 (en) 2012-08-22
US20090246225A1 (en) 2009-10-01
KR20050114625A (ko) 2005-12-06
US8986705B2 (en) 2015-03-24
CN101804202B (zh) 2014-06-18
CN100582244C (zh) 2010-01-20

Similar Documents

Publication Publication Date Title
EP1597400B8 (en) Methods of producing influenza vaccine compositions
EP1824990A4 (en) METHOD FOR PRODUCING INFLUENZA VACCINE COMPOSITIONS
GB0321607D0 (en) Manufacture of pharmaceutical compositions
ZA200609543B (en) Process for the production of an influenza vaccine
HK1067891A1 (en) Influenza vaccine composition
AU2003291668A1 (en) Sacrificial compositions, methods of use thereof, and methods of decomposition thereof
EP1603590A4 (en) INFLUENZA VIRUS VACCINE
HK1102047A1 (en) Refrigerator-temperature stable influenza vaccine compositions
IS7261A (is) N-adamantýlmetýlafleiður og milliefni sem lyfjablöndur og aðferðir til að framleiða þær
EP1745573A4 (en) PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
EP1594544A4 (en) ORAL COMPOSITIONS OF FENRETINIDE WITH INCREASED BIOAVAILABILITY AND METHOD FOR THE APPLICATION THEREOF
AU2003270779A1 (en) Vaccine compositions and adjuvant
AU2003226748A1 (en) Compositions of venlafaxine base
EP2460820B8 (en) Pcv2 immunogenic compositions and methods of producing such compositions
AU2003303744A1 (en) Novel nimesulide compositions
AU2003217900A1 (en) Preparation of unsaturated polyesters
EP1625136A4 (en) PROCESS FOR PREPARING 4-R-SUBSTITUTED 4-DEMETHOXYDAUNORUBICIN
AU2003297766A1 (en) MANUFACTURE OF WATER-SOLUBLE Beta-HYDROXYNITRILES
AU2003208314A1 (en) Novel application of vaccination against tnf-alpha
AU2003298725A1 (en) Preparation of metallotexaphyrins
AU2003239773A1 (en) Preparation of vaccines
AU2003205355A1 (en) Methods of administering gaultherin-containing compositions
AU2003900767A0 (en) Idiotypic vaccine
AU2003236217A1 (en) Method of deseeding pomegranates
AU2003269486A1 (en) An improved process for the preparation of pure nisoldipine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BALU, PALANI

Inventor name: KEMBLE, GEORGE

Inventor name: TRAGER, GEORGE, ROBERT

Inventor name: CHEN, ZHONGYING

Inventor name: YEE, LUISA

Inventor name: PAN, ALFRED, A.

Inventor name: WANG, CHIAOYIN, KATHY

Inventor name: MEHTA, HARSHVARDHAN

Inventor name: TRUONG-LE, VU

Inventor name: TSAO, ERIC

Inventor name: SCHWARTZ, RICHARD, M.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077085

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070808

17Q First examination report despatched

Effective date: 20100305

RTI1 Title (correction)

Free format text: METHODS OF PRODUCING INFLUENZA VACCINE COMPOSITIONS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 572063

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120915

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: MEDLMMUNE, LLC

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004039048

Country of ref document: DE

Effective date: 20121018

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120822

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 572063

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004039048

Country of ref document: DE

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121123

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121224

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1077085

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004039048

Country of ref document: DE

Owner name: MEDIMMUNE, LLC, US

Free format text: FORMER OWNER: MEDIMMUNE VACCINES, INC., MOUNTAIN VIEW, US

Effective date: 20130213

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004039048

Country of ref document: DE

Owner name: MEDIMMUNE, LLC, US

Free format text: FORMER OWNER: MEDIMMUNE VACCINES, INC., MOUNTAIN VIEW, US

Effective date: 20120822

Ref country code: DE

Ref legal event code: R082

Ref document number: 602004039048

Country of ref document: DE

Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU

Effective date: 20130213

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004039048

Country of ref document: DE

Owner name: MEDIMMUNE, LLC, GAITHERSBURG, US

Free format text: FORMER OWNER: MEDIMMUNE VACCINES, INC., MOUNTAIN VIEW, CALIF., US

Effective date: 20120822

Ref country code: DE

Ref legal event code: R081

Ref document number: 602004039048

Country of ref document: DE

Owner name: MEDIMMUNE, LLC, GAITHERSBURG, US

Free format text: FORMER OWNER: MEDIMMUNE VACCINES, INC., MOUNTAIN VIEW, CALIF., US

Effective date: 20130213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121203

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R083

Ref document number: 602004039048

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004039048

Country of ref document: DE

Effective date: 20130523

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: MEDIMMUNE, LLC

REG Reference to a national code

Ref country code: GB

Ref legal event code: S117

Free format text: REQUEST FILED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 2 JULY 2013

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

REG Reference to a national code

Ref country code: GB

Ref legal event code: S13C

Free format text: APPLICATION FILED; APPLICATION FOR A PERSON NOT TO BE MENTIONED AS INVENTOR UNDER SECTION 13(3) BY MEDIMMUNE, LLC FILED ON 11 OCTOBER 2013.

Ref country code: GB

Ref legal event code: S13A

Free format text: APPLICATION FILED; APPLICATION FOR A PERSON TO BE MENTIONED AS INVENTOR UNDER RULE 10(2) BY MEDIMMUNE LLC, FILED ON 11 OCTOBER 2013

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: GB

Ref legal event code: S13A

Free format text: APPLICATION FILED; IN A DECISION OF THE COMPTROLLER DATED 4 NOVEMBER 2013, THE APPLICATION FILED UNDER RULE 10(2) WAS ALLOWED. THE COMPTROLLER FOUND THAT JOHN MICHAEL BERRY AND WEIDONG CUI SHOULD BE MENTIONED AS JOINT INVENTORS AND DIRECTED THAT AN ADDENDUM SLIP MENTIONING THEM AS SUCH BE PREPARED FOR THE GRANTED PATENT FOR THE INVENTION.

Ref country code: GB

Ref legal event code: S13C

Free format text: APPLICATION ALLOWED; IN A DECISION OF THE COMPTROLLER DATED 4 NOVEMBER 2013, THE APPLICATION FILED UNDER SECTION 13(3) WAS ALLOWED. THE COMPTROLLER FOUND THAT GEORGE KEMBLE, ZHONYING CHEN, A. ALFRED PAN, ERIC TSAO, KATHY CHIAOYIN WANG AND PALANI BALU SHOULD NOT HAVE BEEN MENTIONED AS JOINT INVENTORS IN RESPECT OF THE GRANTED PATENT FOR THE INVENTION. THE DECISION SERVES AS A CERTIFICATE TO THIS EFFECT. THE COMPTROLLER ALSO DIRECTED THAT AN ADDENDUM SLIP BE PREPARED FOR THE GRANTED PATENT FOR THE INVENTION STATING THAT GEORGE KEMBLE, ZHONYING CHEN, A. ALFRED PAN, ERIC TSAI, KATHY CHIAOYIN WANG AND PALANI BALU SHOULD NOT HAVE BEEN MENTIONED AS INVENTORS.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130225

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140227

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20140220

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20140227

Year of fee payment: 11

REG Reference to a national code

Ref country code: GB

Ref legal event code: S117

Free format text: REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 02.07.2013 NOT PROCEEDED WITH ON 10.07.2014.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20040225

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130225

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004039048

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150225

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20151030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150225

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150302